The Idorsia drug candidate demonstrated minimal serious treatment-emergent adverse events, with no rebound insomnia or withdrawal symptoms upon discontinuation.
from Front page feed https://ift.tt/2Yaipjv
from Front page feed https://ift.tt/2Yaipjv
Comments
Post a Comment